Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
Abstract
Background: Extensive literature has established equivalent efficacy of early intravenous (IV) to oral antibiotic transition. However, there is variability in adoption across practice settings. Unlike Outpatient Parenteral Antimicrobial Therapy (OPAT) programs, Complex Outpatient Antimicrobial Therapy with Oral Agents (COpAT) programs face significant implementation science challenges. We used a clinical trial with broad enrollment criteria to determine the impact of early oral transition in a real-world setting and studied its influence on practice transformation.
Methods: Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Trial was a pragmatic, randomized controlled trial at 5 hospitals in 1 rural health system. Patients who required 2 or more weeks of IV antibiotics (for all but central nervous system infections) were randomized 2:1 to experimental (early-oral) group or control (IV-only) group. Two primary outcomes and hypotheses were assessed at 3 months: early-oral group safety superiority and efficacy equivalence. Clinical cases of patients who completed the trial were presented at multiple forums.
Results: The trial was stopped early after two-thirds enrollment for a significant safety benefit. Early-oral group demonstrated a significantly lower adverse event rate (3.2% versus 6.5%, P = .02). Lower cumulative hazard for first study-related adverse event in early-oral group (hazard ratio, 0.24; 95% confidence interval, .08-.75; P = .01) appeared to emerge…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.